Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
02 Jun 2016 FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer Genitourinary cancers - Imaging
01 Jun 2016 All European Scientific Articles to be Freely Accessible by 2020 Bioethics, legal and economic issues
31 May 2016 EMA Recommends to Refuse Marketing Authorisation for Ixazomib Haematologic malignancies - Anticancer agents & Biologic therapy
30 May 2016 Withdrawal of the EU Marketing Authorisation Application for Rociletinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
24 May 2016 Responsible and Effective Sharing of Cancer Genome Data Personalised medicine
23 May 2016 Unprecedented Progress in the Treatment of NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
20 May 2016 FDA Grants Accelerated Approval to Nivolumab for the Treatment of Hodgkin Lymphoma Haematologic malignancies - Cancer Immunology and Immunotherapy
19 May 2016 FDA Approves Atezolizumab for Treatment of Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
18 May 2016 Three Generations of Cancer Immunotherapies Cancer Immunology and Immunotherapy
13 May 2016 Can Regulators Influence the Affordability of Medicines? Bioethics, legal and economic issues
12 May 2016 Anti-Proliferative Effect and Predictive Biomarkers to Palbociclib in Early Breast Cancer Breast cancer - Translational research - Anticancer agents & Biologic therapy
11 May 2016 Microwave Ablation for Treating Liver Metastases Gastrointestinal cancers
10 May 2016 Residual Disease in Oncogene-Driven Solid Tumours Anticancer agents & Biologic therapy
09 May 2016 Imatinib in the context of the anticancer immunosurveillance system Anticancer agents & Biologic therapy
06 May 2016 EMA Recommends Granting a Marketing Authorisation for Lutetium (177 Lu) Chloride Imaging - Endocrine cancers